There are three types of opioid receptors: mu (μ), delta (δ), and kappa (K). Opioid-receptor agonists produce analgesia primarily by acting at μ-receptors found in primary afferent sensory neurons, the spinal cord, the brainstem, and the brain.21-23 Presynaptic μ-receptor activation inhibits calcium influx into sensory neurons, which decreases neurotransmitter release. Postsynaptic μ-receptor activation increases K+ conductance, which decreases postsynaptic neurotransmission.
Morphine is a naturally occurring strong, full μ-receptor agonist. However, after oral administration, morphine is rapidly metabolized by hepatic glucuronidation and its bioavailability is low. Oxycodone is a semi-synthetic strong, full μ-receptor agonist. After oral administration its bioavailability is high. Oxycodone is metabolized by glucuronidation to noroxycodone and by the CYP450 isoenzyme 2D6 to oxymorphone; however, oxycodone and not oxymorphone is primarily responsible for analgesia.
Codeine is a naturally occurring weak, full μ-receptor agonist. Its analgesic action is largely dependent on its hepatic demethylation to morphine. Demethylation by the CYP450 isoenzyme 2D6 is subject to genetic polymorphism. Up to 10% of the general population are poor metabolizers of codeine and do not experience analgesia in response to treatment; while another 10% rapidly convert codeine to morphine, which can lead to severe toxicity (including death) even with therapeutic doses.
Hydrocodone is a synthetic weak, full μ-receptor agonist. It is similar in structure to codeine, but hydrocodone is a more effective analgesic. Hydrocodone is demethylated by the CYP450 isoenzyme 2D6 to hydromorphone, which has a much stronger affinity for the μ-receptor than hydrocodone and is primarily responsible for hydrocodone’s analgesic effect. Patients who are CYP450 isoenzyme 2D6 deficient and those on CYP450 isoenzyme 2D6 inhibitors may not achieve adequate analgesia.
Your session is about to expire. Do you want to continue logged in?